Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML

The role of mTORC1 in AML has not yet been proven due to the mixed results of its inhibitors in clinical trials. Here the authors show the real-time dynamics of the mTORC1 pathway in association with AML growth and response to chemotherapy with fluorescent markers, providing guidance for timed inter...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Toshihiko Oki, Francois Mercier, Hiroki Kato, Yookyung Jung, Thomas O. McDonald, Joel A. Spencer, Michael C. Mazzola, Nick van Gastel, Charles P. Lin, Franziska Michor, Toshio Kitamura, David T. Scadden
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/349ab8eb498d4321b364ef08df2b3bd9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:349ab8eb498d4321b364ef08df2b3bd9
record_format	dspace
spelling	oai:doaj.org-article:349ab8eb498d4321b364ef08df2b3bd92021-12-02T15:22:48ZImaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML10.1038/s41467-020-20491-82041-1723https://doaj.org/article/349ab8eb498d4321b364ef08df2b3bd92021-01-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-20491-8https://doaj.org/toc/2041-1723The role of mTORC1 in AML has not yet been proven due to the mixed results of its inhibitors in clinical trials. Here the authors show the real-time dynamics of the mTORC1 pathway in association with AML growth and response to chemotherapy with fluorescent markers, providing guidance for timed intervention with pathway-specific inhibitors.Toshihiko OkiFrancois MercierHiroki KatoYookyung JungThomas O. McDonaldJoel A. SpencerMichael C. MazzolaNick van GastelCharles P. LinFranziska MichorToshio KitamuraDavid T. ScaddenNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Toshihiko Oki Francois Mercier Hiroki Kato Yookyung Jung Thomas O. McDonald Joel A. Spencer Michael C. Mazzola Nick van Gastel Charles P. Lin Franziska Michor Toshio Kitamura David T. Scadden Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML
description	The role of mTORC1 in AML has not yet been proven due to the mixed results of its inhibitors in clinical trials. Here the authors show the real-time dynamics of the mTORC1 pathway in association with AML growth and response to chemotherapy with fluorescent markers, providing guidance for timed intervention with pathway-specific inhibitors.
format	article
author	Toshihiko Oki Francois Mercier Hiroki Kato Yookyung Jung Thomas O. McDonald Joel A. Spencer Michael C. Mazzola Nick van Gastel Charles P. Lin Franziska Michor Toshio Kitamura David T. Scadden
author_facet	Toshihiko Oki Francois Mercier Hiroki Kato Yookyung Jung Thomas O. McDonald Joel A. Spencer Michael C. Mazzola Nick van Gastel Charles P. Lin Franziska Michor Toshio Kitamura David T. Scadden
author_sort	Toshihiko Oki
title	Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML
title_short	Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML
title_full	Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML
title_fullStr	Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML
title_full_unstemmed	Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML
title_sort	imaging dynamic mtorc1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in aml
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/349ab8eb498d4321b364ef08df2b3bd9
work_keys_str_mv	AT toshihikooki imagingdynamicmtorc1pathwayactivityinvivorevealsmarkedshiftsthatsupporttimespecificinhibitortherapyinaml AT francoismercier imagingdynamicmtorc1pathwayactivityinvivorevealsmarkedshiftsthatsupporttimespecificinhibitortherapyinaml AT hirokikato imagingdynamicmtorc1pathwayactivityinvivorevealsmarkedshiftsthatsupporttimespecificinhibitortherapyinaml AT yookyungjung imagingdynamicmtorc1pathwayactivityinvivorevealsmarkedshiftsthatsupporttimespecificinhibitortherapyinaml AT thomasomcdonald imagingdynamicmtorc1pathwayactivityinvivorevealsmarkedshiftsthatsupporttimespecificinhibitortherapyinaml AT joelaspencer imagingdynamicmtorc1pathwayactivityinvivorevealsmarkedshiftsthatsupporttimespecificinhibitortherapyinaml AT michaelcmazzola imagingdynamicmtorc1pathwayactivityinvivorevealsmarkedshiftsthatsupporttimespecificinhibitortherapyinaml AT nickvangastel imagingdynamicmtorc1pathwayactivityinvivorevealsmarkedshiftsthatsupporttimespecificinhibitortherapyinaml AT charlesplin imagingdynamicmtorc1pathwayactivityinvivorevealsmarkedshiftsthatsupporttimespecificinhibitortherapyinaml AT franziskamichor imagingdynamicmtorc1pathwayactivityinvivorevealsmarkedshiftsthatsupporttimespecificinhibitortherapyinaml AT toshiokitamura imagingdynamicmtorc1pathwayactivityinvivorevealsmarkedshiftsthatsupporttimespecificinhibitortherapyinaml AT davidtscadden imagingdynamicmtorc1pathwayactivityinvivorevealsmarkedshiftsthatsupporttimespecificinhibitortherapyinaml
_version_	1718387376835788800

Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML

Ejemplares similares